Sanofi India

With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon

Drug firm Sanofi India on Thursday reported a net profit of Rs 131 crore for the third quarter ended September 2022. The company had posted a net profit of Rs 530 crore in the July-September quarter of last year, the company said in a regulatory filing. The drug firm follows a January-December financial year. Revenue from operations stood at Rs 692 crore in the period under review. The same stood at Rs 754 crore in the corresponding period previous year. The company said the results of the September quarter were not comparable with the same quarter last year as it had transferred its nutraceuticals business to Universal Nutriscience, enabling a gain of Rs 489 crore.

The decline was largely on account of divestment of its nutraceutical business and a few key brands.

Products in the price control list and growth of the non-power brand portfolio will be key monitorables

He will transition from being Sanofi's GM, Consumer Healthcare business in Brazil to the new role in India as soon as regulatory approvals are in place

Closing Bell: Benchmark indices clocked their biggest one-day fall since March 2020 as Russia invaded Ukraine, rattling global markets

Insurance related stocks could see some action as the India Protection Quotient (IPQ) survey 4, stated that term insurance ownership has gone up from 36 per cent to 43 per cent in the last two years.

Drug firm Sanofi India on Thursday said its Managing Director Rajaram Narayanan has put in his papers

The company's revenue from operations rose to Rs 754.5 crore as compared to Rs 686.6 crore in the year-ago period

Revenue from operations of the company stood at Rs 789.1 crore for the quarter under consideration

Growth led by power brands and new launches could recover as pandemic impact wanes

SBI Cards and Payment Services had raised Rs 550 crore by issuing bonds on a private placement basis

The company reported net profit of Rs 123 cr for the quarter ended December, 31 2020, an increase of 27% from year-ago period

In December last year, Sanofi had said it was targeting "earliest potential approval" of the shot in the second half of 2021, following positive preclinical data

The French company, which stunned investors last year with the delay of a COVID-19 vaccine candidate, confirmed an operating income margin target of 30%

Analysts see 19 per cent annual growth in earnings during FY20-22 with significant rise in return ratios post sale of a facility

PARIS (Reuters) - French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments

The company is working on two of the more than 150 potential vaccines being developed across the world to tackle the Covid-19 pandemic

Early this week, the comany's parent firm Sanofi said it will acquire all of the outstanding shares of US-based Principia Biopharma Inc. for a total approximate aggregate equity value of $3.68 billion

Traders are advised to hold Nifty longs with 11,200 stoploss and keep it trailing as Nifty rises